Clinical Trial: A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205796) titled 'A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants' on Sept. 26.

Brief Summary: The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.

Study Start Date: July 01, 2026

Study Type: INTERVENTIONAL

Condition: Herpes Zoster

Intervention: BIOLOGICAL: HZ Vaccine (IN001)

Formulation for injection

BIOLOGICAL: Shingrix

Sterile suspension for injection...